Physician profile
David E Hon
NPI 1740237510
$1,159.11
in general payments reported to CMS, 2019-2025
14 companies · $773 in 2025
The $773 reported for 2025 was more than what 77% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2021: $33.30 · 2024: $175 · 2025: $773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $947.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $208.34 | 2019-2025 | Invega Sustenna, Spravato |
| Otsuka America Pharmaceutical, INC. | $198.26 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $156.85 | 2024-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $125.88 | 2024-2025 | Uzedy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $114.72 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $84.66 | 2024-2025 | Ingrezza |
| Alkermes, INC. | $82.10 | 2019-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.67 | 2024-2025 | Caplyta |
| Abbvie INC. | $33.30 | 2021 | |
| Sunovion Pharmaceuticals INC. | $25.37 | 2019 | |
| Axsome Therapeutics, INC. | $20.82 | 2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $19.93 | 2024 | |
| Noven Therapeutics, LLC | $19.43 | 2025 | Xelstrym, Secuado |
| Supernus Pharmaceuticals, INC. | $17.78 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.